Cargando…

LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis

Although programmed death-ligand 1 (PD-L1) inhibitors have achieved some therapeutic success in breast cancer, their efficacy is limited by low therapeutic response rates, which is closely related to the immune escape of breast cancer cells. Tissue differentiation inducing non-protein coding RNA (TI...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qin, Li, Guozheng, Ma, Xin, Liu, Lei, Liu, Jiena, Yin, Yanling, Li, Hui, Chen, Yihai, Zhang, Xin, Zhang, Lei, Sun, Liyang, Ai, Jing, Xu, Shouping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892521/
https://www.ncbi.nlm.nih.gov/pubmed/36725842
http://dx.doi.org/10.1038/s41419-023-05609-2
_version_ 1784881341536403456
author Wang, Qin
Li, Guozheng
Ma, Xin
Liu, Lei
Liu, Jiena
Yin, Yanling
Li, Hui
Chen, Yihai
Zhang, Xin
Zhang, Lei
Sun, Liyang
Ai, Jing
Xu, Shouping
author_facet Wang, Qin
Li, Guozheng
Ma, Xin
Liu, Lei
Liu, Jiena
Yin, Yanling
Li, Hui
Chen, Yihai
Zhang, Xin
Zhang, Lei
Sun, Liyang
Ai, Jing
Xu, Shouping
author_sort Wang, Qin
collection PubMed
description Although programmed death-ligand 1 (PD-L1) inhibitors have achieved some therapeutic success in breast cancer, their efficacy is limited by low therapeutic response rates, which is closely related to the immune escape of breast cancer cells. Tissue differentiation inducing non-protein coding RNA (TINCR), a long non-coding RNA, as an oncogenic gene associated with the progression of various malignant tumors, including breast cancer; however, the role of TINCR in tumor immunity, especially in breast cancer, remains unclear. We confirmed that TINCR upregulated PD-L1 expression in vivo and in vitro, and promoted the progression of breast cancer. Next, we revealed that TINCR knockdown can significantly improve the therapeutic effect of PD-L1 inhibitors in breast cancer in vivo. Mechanistically, TINCR recruits DNMT1 to promote the methylation of miR-199a-5p loci and inhibit its transcription. Furthermore, in the cytoplasm, TINCR potentially acts as a molecular sponge of miR-199a-5p and upregulates the stability of USP20 mRNA through a competing endogenous RNA (ceRNA) regulatory mechanism, thus promoting PD-L1 expression by decreasing its ubiquitination level. IFN-γ stimulation activates STAT1 by phosphorylation, which migrates into the nucleus to promote TINCR transcription. This is the first study to describe the regulatory role of TINCR in breast cancer tumor immunity, broadening the current paradigm of the functional diversity of TINCR in tumor biology. In addition, our study provides new research directions and potential therapeutic targets for PD-L1 inhibitors in breast cancer.
format Online
Article
Text
id pubmed-9892521
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98925212023-02-03 LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis Wang, Qin Li, Guozheng Ma, Xin Liu, Lei Liu, Jiena Yin, Yanling Li, Hui Chen, Yihai Zhang, Xin Zhang, Lei Sun, Liyang Ai, Jing Xu, Shouping Cell Death Dis Article Although programmed death-ligand 1 (PD-L1) inhibitors have achieved some therapeutic success in breast cancer, their efficacy is limited by low therapeutic response rates, which is closely related to the immune escape of breast cancer cells. Tissue differentiation inducing non-protein coding RNA (TINCR), a long non-coding RNA, as an oncogenic gene associated with the progression of various malignant tumors, including breast cancer; however, the role of TINCR in tumor immunity, especially in breast cancer, remains unclear. We confirmed that TINCR upregulated PD-L1 expression in vivo and in vitro, and promoted the progression of breast cancer. Next, we revealed that TINCR knockdown can significantly improve the therapeutic effect of PD-L1 inhibitors in breast cancer in vivo. Mechanistically, TINCR recruits DNMT1 to promote the methylation of miR-199a-5p loci and inhibit its transcription. Furthermore, in the cytoplasm, TINCR potentially acts as a molecular sponge of miR-199a-5p and upregulates the stability of USP20 mRNA through a competing endogenous RNA (ceRNA) regulatory mechanism, thus promoting PD-L1 expression by decreasing its ubiquitination level. IFN-γ stimulation activates STAT1 by phosphorylation, which migrates into the nucleus to promote TINCR transcription. This is the first study to describe the regulatory role of TINCR in breast cancer tumor immunity, broadening the current paradigm of the functional diversity of TINCR in tumor biology. In addition, our study provides new research directions and potential therapeutic targets for PD-L1 inhibitors in breast cancer. Nature Publishing Group UK 2023-02-01 /pmc/articles/PMC9892521/ /pubmed/36725842 http://dx.doi.org/10.1038/s41419-023-05609-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Qin
Li, Guozheng
Ma, Xin
Liu, Lei
Liu, Jiena
Yin, Yanling
Li, Hui
Chen, Yihai
Zhang, Xin
Zhang, Lei
Sun, Liyang
Ai, Jing
Xu, Shouping
LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title_full LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title_fullStr LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title_full_unstemmed LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title_short LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
title_sort lncrna tincr impairs the efficacy of immunotherapy against breast cancer by recruiting dnmt1 and downregulating mir-199a-5p via the stat1–tincr-usp20-pd-l1 axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892521/
https://www.ncbi.nlm.nih.gov/pubmed/36725842
http://dx.doi.org/10.1038/s41419-023-05609-2
work_keys_str_mv AT wangqin lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT liguozheng lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT maxin lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT liulei lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT liujiena lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT yinyanling lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT lihui lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT chenyihai lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT zhangxin lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT zhanglei lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT sunliyang lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT aijing lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis
AT xushouping lncrnatincrimpairstheefficacyofimmunotherapyagainstbreastcancerbyrecruitingdnmt1anddownregulatingmir199a5pviathestat1tincrusp20pdl1axis